News | May 26, 2025
Torrent Pharma reports Q4 FY25 PAT at Rs. 498 Cr
The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore
The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
For the full year FY25, net profit soared 12x to Rs 345 crore
Allopurinol is used to prevent or lower high uric acid levels in the blood
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
The company has posted net profit of Rs. 40.88 crores for the Financial Year ended March 31, 2025
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
Subscribe To Our Newsletter & Stay Updated
